Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

被引:0
|
作者
Yun, Ji Hyun [1 ]
Chang, Euijin [2 ]
Bae, Seongman [2 ,3 ]
Jung, Jiwon [2 ]
Kim, Min Jae [2 ]
Chong, Yong Pil [2 ]
Kim, Sung-Han [2 ]
Choi, Sang-Ho [2 ]
Lee, Sang-Oh [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Konkuk Univ, Sch Med, Dept Internal Med, Div Infect Dis,Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Infect Dis, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 08期
关键词
hVISA; vancomycin; treatment failure; risk factors; age; severity; minimal inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; METHICILLIN-RESISTANT; CLINICAL-FEATURES; INFECTIONS; STRAINS; HETERORESISTANCE; SUSCEPTIBILITY; DEFINITION; CRITERIA;
D O I
10.1128/spectrum.00333-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) <= 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus
    冯娜娜
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (02) : 75 - 75
  • [12] The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
    Appelbaum, PC
    CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 : 16 - 23
  • [13] Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
    Howden, Benjamin P.
    Davies, John K.
    Johnson, Paul D. R.
    Stinear, Timothy P.
    Grayson, M. Lindsay
    CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) : 99 - +
  • [14] Heterogeneous Vancomycin-Intermediate Staphylococcus aureus(HVISA) at a Tertiary Hospital in Malaysia
    Hamasalih, Bakhtiyar Mahmood
    Neoh, Hui-Min
    Ibrahim, Rosni
    Nor, Lailatul Akmar Mat
    Jamaluddin, Tengku Zetty Maztura Tengku
    SAINS MALAYSIANA, 2022, 51 (03): : 795 - 801
  • [15] Be alert to the alterations in the biological characteristics in heterogeneous vancomycin-intermediate Staphylococcus aureus
    Zhou, X.
    Dai, Y. Y.
    Ma, X. L.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2012, 30 (02) : 215 - 217
  • [16] Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia
    Naimi, TS
    Anderson, D
    O'Boyle, C
    Boxrud, DJ
    Johnson, SK
    Tenover, FC
    Lynfield, R
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) : 1609 - 1612
  • [17] Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid
    Balkhair, Abdullah
    Al Muharrmi, Zakariya
    Darwish, Laila
    Farhan, Hatem
    Sallam, Mansour
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E227 - E229
  • [18] Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains
    Mehes, Leonora
    Tasko, Szilvia
    Szekely, Annamaria
    Toth, Akos
    Ungvari, Erika
    Erdei, Iren
    Dombradi, Zsuzsanna
    Szabo, Judit
    Marodi, Laszlo
    JOURNAL OF MEDICAL MICROBIOLOGY, 2012, 61 (02) : 198 - 203
  • [19] Accurate assessment of heterogeneous vancomycin-intermediate Staphylococcus aureus nasal carriage
    Charles, PGP
    Howden, BP
    Ward, PB
    Bishop, EJ
    Johnson, PDR
    Grayson, ML
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) : 1071 - 1072
  • [20] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638